These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 38634839)
41. Is it safe to use carbapenems in patients with a history of allergy to penicillin? Sodhi M; Axtell SS; Callahan J; Shekar R J Antimicrob Chemother; 2004 Dec; 54(6):1155-7. PubMed ID: 15486083 [TBL] [Abstract][Full Text] [Related]
42. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group. Romanelli G; Cravarezza P J Antimicrob Chemother; 1995 Jul; 36 Suppl A():109-19. PubMed ID: 8543487 [TBL] [Abstract][Full Text] [Related]
43. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections. Edwards SJ; Emmas CE; Campbell HE Curr Med Res Opin; 2005 May; 21(5):785-94. PubMed ID: 15969878 [TBL] [Abstract][Full Text] [Related]
44. Comparative convulsant potencies of two carbapenem derivatives in C57 and DBA/2 mice. de Sarro A; Imperatore C; Mastroeni P; de Sarro G J Pharm Pharmacol; 1995 Apr; 47(4):292-6. PubMed ID: 7791026 [TBL] [Abstract][Full Text] [Related]
45. The risk of seizures among the carbapenems: a meta-analysis. Cannon JP; Lee TA; Clark NM; Setlak P; Grim SA J Antimicrob Chemother; 2014 Aug; 69(8):2043-55. PubMed ID: 24744302 [TBL] [Abstract][Full Text] [Related]
46. A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem. Wu Y; Chen K; Shi Z; Wang Q Curr Pharm Biotechnol; 2014; 15(8):685-90. PubMed ID: 25051950 [TBL] [Abstract][Full Text] [Related]
47. Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/cilastatin. Maggioni P; Di Stefano F; Facchini V; Irato S; Mancuso S; Colombo M; Massobrio M; Melis GB; Crosignani P J Chemother; 1998 Apr; 10(2):114-21. PubMed ID: 9603636 [TBL] [Abstract][Full Text] [Related]
48. Determination of Total and Unbound Meropenem, Imipenem/Cilastatin, and Cefoperazone/Sulbactam in Human Plasma: Application for Therapeutic Drug Monitoring in Critically Ill Patients. Rao Z; Dang ZL; Li B; Zhu L; Qin HY; Wu XA; Wei YH Ther Drug Monit; 2020 Aug; 42(4):578-587. PubMed ID: 32049891 [TBL] [Abstract][Full Text] [Related]
49. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Wiseman LR; Wagstaff AJ; Brogden RN; Bryson HM Drugs; 1995 Jul; 50(1):73-101. PubMed ID: 7588092 [TBL] [Abstract][Full Text] [Related]
50. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889 [TBL] [Abstract][Full Text] [Related]
51. Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemase-producing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems. Vading M; Samuelsen Ø; Haldorsen B; Sundsfjord AS; Giske CG Clin Microbiol Infect; 2011 May; 17(5):668-74. PubMed ID: 20649801 [TBL] [Abstract][Full Text] [Related]
52. [In vitro emergence of ertapenem resistance in Escherichia coli producing extended-spectrum β-lactamase]. Villar HE; Jugo MB; Visser M; Hidalgo M; Hidalgo G; Maccallini GC Rev Esp Quimioter; 2014 Mar; 27(1):51-5. PubMed ID: 24676243 [TBL] [Abstract][Full Text] [Related]
53. Cross-reactivity and Tolerability of Ertapenem in Patients With IgE-Mediated Hypersensitivity to β-Lactams. Buonomo A; Pascolini L; Rizzi A; Aruanno A; Pecora V; Ricci AG; Mezzacappa S; Di Rienzo A; Centrone M; Nucera E; Schiavino D J Investig Allergol Clin Immunol; 2016; 26(2):100-5. PubMed ID: 27164625 [TBL] [Abstract][Full Text] [Related]
55. Safety of imipenem/cilastatin in neurocritical care patients. Hoffman J; Trimble J; Brophy GM Neurocrit Care; 2009; 10(3):403-7. PubMed ID: 19116700 [TBL] [Abstract][Full Text] [Related]
56. Comparison of in vitro efficacy of ertapenem, imipenem and meropenem in the infections caused by the Enterobacteriaceae strains family. Guzek A; Tomaszewski D; Rybicki Z; Truszczyński A; Barański M; Korzeniewski K Anaesthesiol Intensive Ther; 2013; 45(2):67-72. PubMed ID: 23877897 [TBL] [Abstract][Full Text] [Related]
57. Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients. You X; Dai Q; Hu J; Yu M; Wang X; Weng B; Cheng L; Sun F J Glob Antimicrob Resist; 2024 Mar; 36():252-259. PubMed ID: 38272210 [TBL] [Abstract][Full Text] [Related]
58. Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia. Youssif E; Aseeri M; Khoshhal S J Infect Public Health; 2018; 11(4):486-490. PubMed ID: 29153444 [TBL] [Abstract][Full Text] [Related]
59. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients. Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084 [TBL] [Abstract][Full Text] [Related]
60. Effects of beta-lactam antibiotics imipenem/cilastatin and cefodizime on cellular and humoral immune responses in BALB/c-mice. Grochla I; Ko HL; Beuth J; Roszkowski K; Roszkowski W; Pulverer G Zentralbl Bakteriol; 1990 Nov; 274(2):250-8. PubMed ID: 2085374 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]